Financial insights of LSTA

MyFinsight

For the quarter ending 2026-03-31.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Revenue	-	65*	0	70
General and administrative	-	-	2,455	2,685
Research and development	1,204	1,631*	1,959	2,253
General and administrative	3,738	2,720*	-	-
Total operating expenses	4,942	4,351*	4,414	4,938
Operating loss	-4,942	-4,286*	-4,414	-4,868
Investment income, net	120	208*	183	216
Other expense, net	-54	-107*	-18	-7
Total other income	66	100*	165	209
Net loss before benefit from income taxes and noncontrolling interests	-4,876	-4,186*	-4,249	-4,659
Benefit from income taxes	-387	-962*	0	0
Net loss	-4,489	-3,224*	-4,249	-4,659
Less - net income (loss) attributable to noncontrolling interests	0	0*	0	0
Net loss attributable to lisata therapeutics, inc. common stockholders	-4,489	-3,224	-4,249	-4,659

Basic EPS	-0.5	-0.37	-0.49	-0.54
Diluted EPS	-0.5	-0.37	-0.49	-0.54
Basic Average Shares	9,006,000	8,718,000	8,738,000	8,605,000
Diluted Average Shares	9,006,000	8,718,000	8,738,000	8,605,000

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.